The stock demonstrated strong momentum today, opening with a gap up of 4.93% and achieving an intraday high that matched its new peak price of Rs.1971.25, representing a 5% rise during the trading session. This performance outpaced the sector by 5.29%, underscoring Fredun Pharmaceuticals' relative strength amid broader market fluctuations.
Fredun Pharmaceuticals has recorded gains for three consecutive trading days, accumulating a return of 15.57% over this period. The stock is currently trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum and positive technical positioning.
Our latest monthly pick, this micro-cap from Pharmaceuticals & Biotechnology, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- Market-beating performance
- Committee-backed winner
- Pharmaceuticals & Biotechnology standout
Over the past year, Fredun Pharmaceuticals has delivered a remarkable return of 182.89%, significantly outperforming the Sensex, which recorded a 9.45% return over the same period. The stock's 52-week low was Rs.635, highlighting the extent of its upward trajectory in the last twelve months.
Financially, the company has shown robust growth metrics. Net sales for the latest quarter stood at Rs.145.30 crores, reflecting a year-on-year growth rate of 35.35%. Operating profit for the quarter has been recorded at a growth rate of 55.03%, while net profit growth reached 127.87%, indicating strong profitability trends. The company has reported positive results for six consecutive quarters, reinforcing its consistent performance.
Fredun Pharmaceuticals' operating profit to interest ratio for the quarter is at 2.89 times, and profit before tax excluding other income is Rs.13.01 crores, growing at 71.64%. These figures suggest a healthy operational efficiency and financial leverage management.
The company’s return on capital employed (ROCE) stands at 20.2%, accompanied by an enterprise value to capital employed ratio of 3.3, which points to an attractive valuation relative to its capital base. Compared to its peers, Fredun Pharmaceuticals is trading at a discount to average historical valuations, adding context to its current market positioning.
Want to dive deeper on Fredun Pharmaceuticals ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- Real-time research report
- Complete fundamental analysis
- Peer comparison included
In the broader market context, the Sensex opened positively with a gain of 91.42 points but later declined by 393.30 points, trading at 84,649.07, down 0.36%. The index remains close to its own 52-week high of 85,290.06, just 0.76% away, and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend.
Despite Fredun Pharmaceuticals’ market capitalisation grade of 4 and a Mojo Score of 77.0, domestic mutual funds hold no stake in the company. This absence of mutual fund participation may reflect a cautious stance or valuation considerations within institutional circles, despite the company’s strong financial and market performance.
Fredun Pharmaceuticals’ sector, Pharmaceuticals & Biotechnology, continues to be a dynamic space, and the company’s recent price action and financial results highlight its capacity to generate market-beating returns over both the short and long term. The stock’s current trading levels, supported by solid fundamentals and technical indicators, mark a noteworthy phase in its market journey.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
